Sutro Biopharma Stock Forecast, Price & News

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sutro Biopharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Sutro Biopharma stock.
View analyst ratings for Sutro Biopharma or view top-rated stocks.

Wall Street analysts have given Sutro Biopharma a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Sutro Biopharma wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Sutro Biopharma is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Sutro Biopharma.

Sutro Biopharma, Inc. (NASDAQ:STRO) issued its quarterly earnings results on Thursday, May, 6th. The company reported ($0.66) EPS for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.04. Sutro Biopharma had a negative trailing twelve-month return on equity of 40.67% and a negative net margin of 85.39%.
View Sutro Biopharma's earnings history.

Sutro Biopharma's stock was trading at $8.11 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, STRO shares have increased by 130.9% and is now trading at $18.73.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 12-month price targets for Sutro Biopharma's stock. Their forecasts range from $18.00 to $37.00. On average, they anticipate Sutro Biopharma's share price to reach $24.60 in the next twelve months. This suggests a possible upside of 31.3% from the stock's current price.
View analysts' price targets for Sutro Biopharma or view top-rated stocks among Wall Street analysts.

11 employees have rated Sutro Biopharma CEO William J. Newell on Glassdoor.com. William J. Newell has an approval rating of 100% among Sutro Biopharma's employees. This puts William J. Newell in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Sutro Biopharma include Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Bavarian Nordic A/S (BVNRY), Vericel (VCEL), NanoString Technologies (NSTG), Revolution Medicines (RVMD), Sorrento Therapeutics (SRNE), Editas Medicine (EDIT), Rubius Therapeutics (RUBY), Instil Bio (TIL), Kymera Therapeutics (KYMR), bluebird bio (BLUE), Alector (ALEC), Immunocore (IMCR) and C4 Therapeutics (CCCC).
View all of STRO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sutro Biopharma investors own include Pfizer (PFE), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), IDEAYA Biosciences (IDYA), Provention Bio (PRVB), Sorrento Therapeutics (SRNE), Xeris Pharmaceuticals (XERS) and AbbVie (ABBV).

(STRO) raised $75 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Sutro Biopharma trades on the NASDAQ under the ticker symbol "STRO."

Sutro Biopharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.73%), Franklin Resources Inc. (5.74%), First Light Asset Management LLC (4.46%), Holocene Advisors LP (3.09%), Loomis Sayles & Co. L P (2.94%) and Suvretta Capital Management LLC (2.79%). Company insiders that own Sutro Biopharma stock include Arturo Md Molina, John Gordon Freund, Trevor Hallam and William J Newell.
View institutional ownership trends for Sutro Biopharma.

STRO stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, Point72 Asset Management L.P., Tekla Capital Management LLC, Pentwater Capital Management LP, Schonfeld Strategic Advisors LLC, Parkman Healthcare Partners LLC, Goldman Sachs Group Inc., and D. E. Shaw & Co. Inc.. Company insiders that have sold Sutro Biopharma company stock in the last year include John Gordon Freund, and Trevor Hallam.
View insider buying and selling activity for Sutro Biopharma or view top insider-selling stocks.

STRO stock was acquired by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, First Light Asset Management LLC, Morgan Stanley, Franklin Resources Inc., BlackRock Inc., Holocene Advisors LP, Compagnie Lombard Odier SCmA, and Dimensional Fund Advisors LP. Company insiders that have bought Sutro Biopharma stock in the last two years include Arturo Md Molina, and William J Newell.
View insider buying and selling activity for Sutro Biopharma or or view top insider-buying stocks.

Shares of STRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STRO stock can currently be purchased for approximately $18.73.

Sutro Biopharma has a market capitalization of $863.70 million and generates $42.72 million in revenue each year. The company earns $-32,130,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis.

Sutro Biopharma employs 195 workers across the globe.

The official website for Sutro Biopharma is www.sutrobio.com.

Sutro Biopharma is headquartered at 310 Utah Avenue Suite 150, South San Francisco CA, 94080.

Sutro Biopharma's mailing address is 310 Utah Avenue Suite 150, South San Francisco CA, 94080. The company can be reached via phone at 650-392-8412 or via email at [email protected]